ClinicalTrials.gg
Active, not recruitingNCT07004972Updated Apr 28, 2026

A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

A Phase 4 interventional study of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy, sponsored by Bristol-Myers Squibb. Active, not recruiting at 24 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.

Planned enrollment
14th of 21
50 · median 75
Started
2025
with 1 other
Phase 4
4 of 21
2 open now
Registered
18th of 21
by date
Lead sponsor
10 of 21
Bristol-Myers Squibb

Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 14th largest by planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 4, and was the 18th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MYK-461

MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and effectiveness of mavacamten in adults with obstructive hypertrophic cardiomyopathy in India.

03

Conditions studied

  • Symptomatic Obstructive Hypertrophic Cardiomyopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with obstructive hypertrophic cardiomyopathy (HCM) consistent with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines.
  • Has unexplained LV hypertrophy with nondilated ventricular chambers in the absence of other cardiac (ie, hypertension, aortic stenosis) or systemic disease and with maximal LV wall thickness ≥ 15 mm (or ≥ 13 mm with positive family history of hypertrophic cardiomyopathy).
  • Has LVOT (Valsalva left ventricular outflow tract) peak gradient ≥ 50 mmHg during screening as assessed by TTE at rest or with Valsalva maneuver.
  • Has LVOT peak gradient with Valsalva maneuver at screening TTE of ≥ 30 mmHg.
  • Has adequate acoustic windows to enable accurate TTEs.
  • Has (NYHA) Class II or III symptoms at screening.
  • Body weight is greater than 45 kg at screening.
  • Documentation of ≥ 55% at rest of screening TTE.

Exclusion criteria

Exclusion Criteria

  • Known infiltrative or storage disorder causing cardiac hypertrophy that mimics obstructive hypertrophic cardiomyopathy, such as Fabry disease, amyloidosis, or Noonan syndrome with LV hypertrophy.
  • Has paroxysmal atrial fibrillation present per the investigator's evaluation of the participant's at the time of screening.
  • Has persistent or permanent atrial fibrillation not on anticoagulation for at least 4 weeks prior to screening and/or not adequately rate controlled within 6 months prior to screening. (Note: Participants with persistent or permanent atrial fibrillation who are anticoagulated and adequately rate-controlled are allowed).
  • Has a history of syncope with exercise within 6 months prior to screening.
  • History of sustained ventricular tachyarrhythmia (> 30 seconds) within 6 months prior to screening.
  • Has documented obstructive coronary artery disease (> 70% stenosis in one or more epicardial coronary arteries) or history of myocardial infarction.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Mavacamten

    Drug: Mavacamten

Interventions

  • Specified dose on specified days

    Also known as: BMS-986427

06

What researchers measure

Primary outcomes

  1. Incidence of serious Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to Week 48

Secondary outcomes

  1. Number of participants with major adverse cardiac events

    Major adverse cardiac events includes cardiovascular \[CV\] death, non-fatal stroke, nonfatal myocardial infarction and hospitalization for heart failure

    Time frame: Up to Week 48

  2. Number of participants with CV hospitalization

    Time frame: Up to Week 48

  3. Number of participants with heart failure (HF) events

    HF includes HF related hospitalizations and urgent emergency room \[ER\]/outpatient visits

    Time frame: Up to Week 48

  4. Number of participants with atrial fibrillation/flutter

    Time frame: Up to Weeks 48

  5. Number of participants with syncope

    Time frame: Up to Week 48

  6. Number of participants with left ventricular ejection fraction (LVEF) < 50%

    Time frame: Up to Week 30

  7. Number of participants with left ventricular ejection fraction (LVEF) < 45%

    Time frame: Up to Week 30

  8. Number of participants with left ventricular ejection fraction (LVEF) < 40%

    Time frame: Up to Week 30

  9. Number of participants with left ventricular ejection fraction (LVEF) < 30%

    Time frame: Up to Week 30

  10. Number of participants with non-serious AEs

    Time frame: Up to Week 48

  11. Change from baseline to Week 30 in Valsalva left ventricular outflow tract (LVOT) peak gradient

    Time frame: Up to Week 30

  12. Change from baseline to Week 30 in resting LVOT peak gradient

    Time frame: Up to Week 30

  13. Change from baseline to Week 30 in hs-troponin-I

    Time frame: Up to Week 30

  14. Change from baseline to Week 30 in N-terminal pro b-type natriuretic peptide (NT-proBNP)

    Time frame: Up to Week 30

  15. Proportion of participants with at least 1 class improvement in New York Heart Association (NYHA) functional class from baseline to Week 30

    The New York Heart Association (NYHA) functional classification of heart failure assigns participants to 1 of 4 categories based on the participant's symptoms. Heart failure classification will be assessed by the Investigator at specified timepoints in the study. NYHA class at Week 30 will be compared to baseline and the proportion of participants with an improvement of at least one class will be determined.

    Time frame: Up to Week 30

07

Study locations

24 sites
  • Local Institution - 0014
    Hyderabad, Andhra Pradesh 500095, India
  • Local Institution - 0011
    Ahmedabad, Gujarat 380060, India
  • Local Institution - 0006
    Surat, Gujarat 395001, India
  • Local Institution - 0020
    Gurgaon, Haryana 122001, India
  • Medanta Heart Institute
    Gurgaon, Haryana 122001, India
  • Local Institution - 0004
    Belagavi, Karnataka 590010, India
  • Local Institution - 0008
    Mangalore, Karnataka 575007, India
  • Local Institution - 0002
    Ernākulam, Kerala 682041, India
  • Local Institution - 0001
    Kottayam, Kerala 686016, India
  • Local Institution - 0012
    Aurangabad, Maharashtra 431005, India
  • Local Institution - 0025
    Mumbai, Maharashtra 400012, India
  • Local Institution - 0025
    Mumbai, Maharashtra 400022, India
  • Local Institution - 0013
    Nagpur, Maharashtra 440015, India
  • Local Institution - 0019
    Nagpur, Maharashtra 440022, India
  • Local Institution - 0024
    Nagpur, Maharashtra 441108, India
  • Local Institution - 0010
    Pune, Maharashtra 411011, India
  • Local Institution - 0021
    New Delhi, National Capital Territory of Delhi 110029, India
  • Local Institution - 0005
    New Delhi, National Capital Territory of Delhi 110060, India
  • Local Institution - 0007
    Bikaner, Rajasthan 334003, India
  • Local Institution - 0003
    Chennai, Tamil Nadu 600002, India
  • Local Institution - 0022
    Aligarh, Uttar Pradesh 202002, India
  • Laxmipat Singhania Institute of Cardiology
    Kanpur, Uttar Pradesh 208002, India
  • Local Institution - 0023
    Kanpur, Uttar Pradesh 208002, India
  • Local Institution - 0017
    Kolkata, West Bengal 700027, India
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2025
First posted
Jun 4, 2025
StartActual
Sep 4, 2025
Primary completionEst.
Dec 13, 2027
CompletionEst.
Dec 13, 2027
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07004972
Responsible party
Sponsor
First posted
Jun 4, 2025
Start date
Sep 4, 2025
Primary completion
Dec 13, 2027 (estimated)
Completion
Dec 13, 2027 (estimated)
Last update
Apr 28, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MYK-461

Start the discussion